Results 121 to 130 of about 208,148 (266)

Pediatric chronic myeloid leukemia in myeloid blast crisis

Autopsy and Case Reports, 2023
Chronic myeloid leukemia (CML) accounts for 2-3% of childhood leukemias. About 5% of cases present in a blastic phase of CML which clinically and morphologically mimics more common acute leukemias of childhood.
Biswajit Dey, Anirban Dutta
doaj  

Research progress on fusion genes in tumours

Clinical and Translational Discovery, Volume 4, Issue 4, August 2024.
Abstract Background The concept of gene fusion describes the process of fusing two genes into one, which is closely linked to tumour occurrence and development and may even be the direct cause of some tumours. Due to their tumour‐specific expression and ability to drive tumour occurrence and development, there is great potential for fusion genes to be
Yinyi Chang, Zitong Zhao, Yongmei Song
wiley   +1 more source

The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era

Revista Brasileira de Hematologia e Hemoterapia, 2011
Tyrosine kinase inhibitors have changed the management and outcomes of chronic myeloid leukemia patients. Quantitative polymerase chain reaction is used to monitor molecular responses to tyrosine kinase inhibitors.
Ilana Zalcberg Renault, Vanesa Scholl, Rocio Hassan, Paola Capelleti, Marcos de Lima, Jorge Cortes   +5 more
doaj   +1 more source

A mathematical model for chemoimmunotherapy of chronic lymphocytic leukemia [PDF]

arXiv, 2018
Immunotherapy is currently regarded as the most promising treatment to fight against cancer. This is particularly true in the treatment of chronic lymphocytic leukemia, an indolent neoplastic disease of B-lymphocytes which eventually causes the immune system's failure.
arxiv  

Impaired DNA replication within progenitor cell pools promotes leukemogenesis. [PDF]

, 2005
Impaired cell cycle progression can be paradoxically associated with increased rates of malignancies. Using retroviral transduction of bone marrow progenitors followed by transplantation into mice, we demonstrate that inhibition of hematopoietic ...
Ames, Anderson, Andriy Marusyk, Begg, Blagosklonny, Calabretta, Castor, Chang, Choi, Christensen, Christopher C Porter, Christopher Kemp, DeGregori, Dimova, Field, Furgerson, Ganna Bilousova, Gottlieb, Greaves, Hanahan, Hariharan, Jacks, James DeGregori, Jamieson, Just, Kinder, Li, Li, Lightfoot, Lin, Luch, Lundin, Matioli, Milner, Murga, Passegue, Pear, Penit, Pui, Robert D Cardiff, Ryan, Saintigny, Sawyers, Schaefer, Shechter, Sirard, Skibola, Skorski, Spangrude, Sterkers, Van Etten, Wallace-Brodeur, Wong, Wu, Yamasaki, Zhang, Zhu, Zimmerman   +57 more
core   +3 more sources

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

Blood, 2003
Clinical studies have shown that the tyrosine kinase inhibitor STI571 effectively controls BCR-ABL-positive chronic myelogenous leukemia (CML). However, disease progression while on STI571 therapy has been reported, suggesting de novo or intrinsic ...
N. Donato, J. Wu, J. Stapley, G. Gallick, Hui-Kuan Lin, R. Arlinghaus, M. Talpaz   +6 more
semanticscholar   +1 more source

Acute lymphoblastic leukemia may develop as a result of rapid transformation of a lymphoblast triggered by repeated bone-remodeling during bone-growth [PDF]

arXiv, 2018
Acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) are two major forms of leukemia that arise from lymphoid cells (LCs). ALL occurs mostly in children and CLL occurs mainly in old people. However, the Philadelphia-chromosome-positive ALL (Ph+-ALL) and the Ph-like ALL occur in both children and adults.
arxiv  

Optimized Treatment Schedules for Chronic Myeloid Leukemia [PDF]

, 2016
Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients. Recent studies have shown that resistance mutations that preexist treatment can be detected in a substan ...
arxiv   +1 more source

Fusion Gene Bcr-abl : From Etiopathogenesis to the Management of Chronic Myeloid Leukemia [PDF]

, 2017
Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm. CML is relative frequent disorder. Most of CML patients have Philadelphia chromosome (Ph),which is derived from a reciprocal translocation between chromosome 9 and 22, t(9;22)(q34;ql1 ...
Sholikah, T. A. (Tri)
core   +2 more sources

[The mechanisms of taxodione-induced apoptosis in BCR-ABL-positive leukemia cells].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2019
Chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) are caused by a fusion protein, BCR-ABL, which induces cellular transformation by activating the signaling molecules, STAT5 and Akt. The specific BCR-ABL inhibitors including imatinib,
Yuki Uchihara, K. Tago, M. Funakoshi-Tago   +2 more
semanticscholar   +1 more source